<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769325</url>
  </required_header>
  <id_info>
    <org_study_id>CSM2016001</org_study_id>
    <nct_id>NCT02769325</nct_id>
  </id_info>
  <brief_title>Atropine in Laparoscopic Gynaecological Surgery</brief_title>
  <acronym>ALGOS</acronym>
  <official_title>Atropine in Laparoscopic Gynaecological Surgery (The ALGOS Trial) A Randomised, Double Blind, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Santa Maria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Santa Maria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blinded, randomised controlled trial that will compare atropine to placebo
      for postoperative pain in laparoscopic gynaecological surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients that meet eligibility criteria will receive a standardised general anesthesia based
      on sevoflurane and opioids and will be randomised in two groups, using computer generated
      randomisation system. Allocation concealment is established on opaque envelopes that contain
      random allocation.

      Anesthesia depth will be measured by Bispectral index (BIS), titration of sevoflurane to a
      BIS of 45-60. In case of neuromuscular block reversal at the end of surgery, sugammadex will
      be administered.

      At induction, 1 mg IV atropine 0.1% OR 10ml saline will be administered, depending on group
      allocation, on a syringe prepared by an anaesthesiologist not involved in the study.

      Patients will receive ketorolac 30 mg/8h, acetaminophen 1g/8h and a morphine IV patient
      controlled anaesthesia pump (PCA) 0-1-8 Outcomes will be evaluated at the postoperative care
      unit (PACU) and 24 postoperative hours by an investigator blinded to study group
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hours morphine consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>morphine consumption, measured 24 post hours, in mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Visual analog scale at 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain visual analog scale at postanesthesia care unit</measure>
    <time_frame>2 hours post</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with postoperative nausea and/or vomiting</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction, on a qualitative scale</measure>
    <time_frame>up to three days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients that refer palpitations</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients that refer mouth dryness</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients that refer blurred vision</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Laparoscopic Surgery</condition>
  <condition>Gynecology</condition>
  <arm_group>
    <arm_group_label>Atropine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients under a standardised general surgery will receive 1mg atropine (10ml) at induction of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients under a standardised general surgery will receive 10 ml of saline at induction of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine</intervention_name>
    <description>IV atropine 0.1%, 10 ml</description>
    <arm_group_label>Atropine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV saline, 10 ml</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60</description>
    <arm_group_label>Atropine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugammadex</intervention_name>
    <description>Patients will receive sugamadex for neuromuscular reversion, if necessary</description>
    <arm_group_label>Atropine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period</description>
    <arm_group_label>Atropine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine PCA</intervention_name>
    <description>Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout</description>
    <arm_group_label>Atropine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rocuronium</intervention_name>
    <description>general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation</description>
    <arm_group_label>Atropine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol</description>
    <arm_group_label>Atropine</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesia (ASA) Class I-II, gynaecological laparoscopic surgery
             lasting â‰¥30' of laparoscopic time, BMI &lt;35

        Exclusion Criteria:

          -  Known allergies to study drugs, concomitant surgeries, patients with closed angle
             glaucoma, history of coronary disease or heart insufficiency, beta.blockers
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinica Santa Maria</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinica Santa Maria</investigator_affiliation>
    <investigator_full_name>David Torres</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>atropine</keyword>
  <keyword>pain, postoperative</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

